ClinicalTrials.gg
CompletedNCT04128787Updated Jul 21, 2021

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

A Phase 1 interventional study of AG881 Formulation 1 and AG881 Formulation 2 in Healthy Volunteers, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-21.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the single-dose pharmacokinetics (PK) of two formulations (Formulation 1 and Formulation 2) of AG-881 and to examine the effect of food and multiple-dose omeprazole on the single-dose PK of AG-881 Formulation 2 in healthy adult participants. This study will also assess the safety and tolerability of single-dose AG-881 (Formulation 1 and 2) alone and of AG-881 Formulation 2 when administered with and without food and when coadministered with omeprazole in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Bioavailability Study
  • Pharmacokinetic study
  • AG-881
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, male or female (WONCBP) participants, 18-55 years of age, inclusive, at Screening.
  2. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study.
  3. (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.
  4. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs, or , as deemed by the Investigator or designee. Liver function tests (serum (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and [total and direct]) must be ≤ the (ULN).
  5. Female participants must be of non- defined as a female who has undergone one of the following sterilization procedures at least 6 months prior to the first dosing: hysteroscopic sterilization; bilateral tubal ligation or bilateral salpingectomy; hysterectomy; bilateral oophorectomy or is with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  6. A non-vasectomized, male participants must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing of study drug. A male who has been vasectomized less than 4 months prior to study first dosing must follow the same restrictions as a non-vasectomized male).
  7. If a male participants, must agree not to donate sperm from the first dosing until 90 days after the last dosing.
  8. Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participant is mentally or legally incapacitated or has significant emotional problems at the time of the Screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the Investigator or designee.
  3. History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or pose an additional risk to the participant (e.g., history or presence of rashes) by their participation in the study.
  4. History of stomach or intestinal surgery that would potentially alter absorption/secretion; or any major surgical procedure within the previous 3 months prior to Screening.
  5. History of severe and/or uncontrolled ventricular arrhythmias, or other factors that increase the risk of or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).
  6. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
  7. History or presence of or idiosyncratic reaction to the study drugs or related compounds.
  8. Any positive responses on the C-SSRS.
  9. Female participants of .
  10. Female participants with a positive pregnancy test or who are lactating.
  11. Positive urine drug or alcohol results at Screening or first check-in.
  12. Positive results at Screening for (HIV) antibodies, surface antigen (HBsAg), or virus (HCV) antibodies.
  13. QT interval Fridericia's formula (QTcF) interval is >450 msec, or QRS interval >110 msec, or PR interval >220 msec, or participants who have findings deemed abnormal with clinical significance by the Investigator or designee at Screening.
  14. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at Screening.
  15. Seated heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at Screening.
  16. Estimated \<90 mL/min at Screening.
  17. Unable to refrain from or anticipates the use of: Any drug, including prescription and non-prescription medications, herbal remedies, and vitamin supplements, beginning 14 days prior to the first dosing and throughout the study. After first dosing, ibuprofen (1.2 g per 24 hour) may be administered at the discretion of Investigator or designee. Hormone replacement therapy will not be allowed; any drugs known to be strong inducers of , CYP2C9, or CYP2C19 enzymes including St. John's Wort and/or, gastric acid reducing agents (e.g., proton-pump inhibitors [with the exception of omeprazole administered as part of the study schedule], H2-receptor antagonists, antacids) for 28 days, or drugs that can prolong the QT interval for 21 days, prior to the first dosing and throughout the study. Appropriate sources (e.g., Flockhart TableTM) will be consulted to confirm lack of PK/Pharmacodynamic (PD) interaction with study drug.
  18. Refuses to abstain from alcohol from 48 hours prior to the first dosing and throughout the study.
  19. Refuses to abstain from grapefruit-containing foods or beverages or Seville orange containing foods or beverages from 14 days prior to the first dosing and throughout the study.
  20. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.
  21. Any allergy or intolerance to food substances which will be provided on the study.
  22. Is lactose intolerant.
  23. Donation of blood or significant blood loss within 56 days prior to the first dose.
  24. Plasma donation within 7 days prior to the first dose.
  25. Receipt of blood or blood products within 2 months prior to the first dose.
  26. Participation in another clinical study within 30 days prior to the first dose. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABCD

    Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.

    Drug: AG881 Formulation 1 · Drug: AG881 Formulation 2 · Drug: Omeprazole

  • Experimental
    Treatment Sequence BCAD

    Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.

    Drug: AG881 Formulation 1 · Drug: AG881 Formulation 2 · Drug: Omeprazole

  • Experimental
    Treatment Sequence CABD

    Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.

    Drug: AG881 Formulation 1 · Drug: AG881 Formulation 2 · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to the Last Observed Non-Zero Concentration (AUC0-t) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  2. Area Under the Concentration-Time Curve From Time 0 to the Last Observed Non-Zero Concentration (AUC0-t) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  3. Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  4. Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  5. Maximum Observed Concentration (Cmax) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  6. Maximum Observed Concentration (Cmax) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  7. Area Under the Concentration-Time Curve, From Time 0 to 504 Hours Postdose (AUC0-504) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  8. Area Under the Concentration-Time Curve, From Time 0 to 504 Hours Postdose (AUC0-504) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  9. Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  10. Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  11. Apparent Terminal Elimination Half-life (t½) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  12. Apparent Terminal Elimination Half-life (t½) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  13. Time Delay Between Drug Administration and the Onset of Absorption (tlag) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  14. Time Delay Between Drug Administration and the Onset of Absorption (tlag) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  15. Time to Reach Maximum Observed Concentration (Tmax) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  16. Time to Reach Maximum Observed Concentration (Tmax) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  17. Apparent Volume of Distribution After Oral (Extravascular) Administration (Vd/F) of AG-881 Formulation 1 without Food

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

  18. Apparent Volume of Distribution After Oral (Extravascular) Administration (Vd/F) of AG-881 Formulation 2 with Food, without Food and when Co-administered with Omeprazole

    Time frame: Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881

Secondary outcomes

  1. Number of Participants with Abnormalities in Triplicate 12-lead Electrocardiograms (ECGs)

    Time frame: Up to 21 days in Period 1, 2, 3 (Each period is 21 days); up to 25 days in Period 4 (Period 4 is 25 days)

  2. Number of Participants with Abnormalities in Vital Sign Measurements

    Vital sign measurements will include body temperature, respiratory rate, blood pressure, and heart rate.

    Time frame: Up to 21 days in Period 1, 2, 3 (Each period is 21 days); up to 25 days in Period 4 (Period 4 is 25 days)

  3. Columbia-suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS is a questionnaire scale to detect emergent suicide symptoms (suicidal ideation or actual suicidal behavior) during the course of this study. Questions are either answered yes/no or are on a scale of 1 (low severity) to 5 (high severity).

    Time frame: Up to 21 days in Period 1, 2, 3 (Each period is 21 days); up to 25 days in Period 4 (Period 4 is 25 days)

  4. Number of Participants with Abnormalities in Clinical Laboratory Tests

    Clinical laboratory assessments will include hematology, serum chemistry, coagulation, and urinalysis.

    Time frame: Up to 21 days in Period 1, 2, 3 (Each period is 21 days); up to 25 days in Period 4 (Period 4 is 25 days)

  5. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence associated with the use of a drug, whether or not considered drug-related.

    Time frame: Up to 28 Days After Last Dose of Study Drug (Up to 91 days)'

  6. Number of Participants with Abnormalities in Physical Examinations

    Physical examination will include, examination of skin, neurological, respiratory, cardiovascular, and gastrointestinal systems.

    Time frame: Up to 21 days in Period 1, 2, 3 (Each period is 21 days); up to 25 days in Period 4 (Period 4 is 25 days)

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2019
First posted
Oct 16, 2019
StartActual
Sep 30, 2019
Primary completionActual
Dec 18, 2019
CompletionActual
Dec 18, 2019
Last update
Jul 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04128787
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Sep 30, 2019
Primary completion
Dec 18, 2019
Completion
Dec 18, 2019
Last update
Jul 21, 2021

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorasidenib · Omeprazole

Start the discussion